Loading company…
PreComb Therapeutics develops patient-derived 3D tumor models for precision oncology and drug testing.
Founded in 2018 and based in Switzerland, PreComb Therapeutics develops its 3DTwin technology to create patient-derived 3D tumor models for drug testing. Its work supports research and drug development by modeling cancer microenvironments. In December 2024, the company raised CHF 1.3 mn in funding, with investors including Kinled Holding and LongeVC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in